Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 3/20 | 0.60 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.60 |
| ▸ | CDC7 | O00311 | 1/20 | 0.35 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.34 |
| ▸ | NAMPT | P43490 | 2/20 | 0.34 |
| ▸ | GCGR | P47871 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5666621 | 1.00 | MAPK14 (0.60) | MAPK14MAPK11CDC7PARP10NAMPT | |
| SCHEMBL5651405 | 0.93 | MAPK14 (0.61) | MAPK14MAPK11NAMPTGCGRKCNH2 | |
| SCHEMBL6219302 | 0.91 | MAPK14 (0.71) | MAPK14MAPK11GCGRRIPK3 | |
| SCHEMBL5650802 | 0.90 | MAPK11 (0.58) | MAPK14MAPK11KCNH2 | |
| SCHEMBL5751855 | 0.90 | MAPK11 (0.58) | MAPK14MAPK11KCNH2 | |
| SCHEMBL5649753 | 0.89 | MAPK11 (0.47) | MAPK14MAPK11CDC7 | |
| SCHEMBL6218785 | 0.89 | MAPK14 (0.65) | MAPK14MAPK11GCGRRIPK3 | |
| SCHEMBL5665083 | 0.88 | MAPK11 (0.58) | MAPK14MAPK11 | |
| SCHEMBL5646091 | 0.88 | MAPK14 (0.56) | MAPK14MAPK11GCGRRIPK3 | |
| SCHEMBL5650805 | 0.88 | MAPK11 (0.58) | MAPK14MAPK11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070049620-A1 | Cyclic tertiary amine compound | SANKYO COMPANY, LIMITED (JP) | 2007-03-01 | — | — | US | claimed |
| EP-1632488-A1 | CYCLIC TERTIARY AMINE COMPOUND | Sankyo Company, Limited (JP) | 2006-03-08 | — | — | EP | claimed |
| US-20070049620-A1 | Cyclic tertiary amine compound | SANKYO COMPANY, LIMITED (JP) | 2007-03-01 | — | — | US | disclosed |
| EP-1632488-A1 | CYCLIC TERTIARY AMINE COMPOUND | Sankyo Company, Limited (JP) | 2006-03-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070049620-A1 | Cyclic tertiary amine compound | MYD88, IL5, BRD4 | MAPK14 467/4885MAPK11 520/4885CDC7 577/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.